Cyfuse Biomedical K.K. Income Statement

Financials in millions JPY. Fiscal year is January - December.

Millions JPY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	230	54	61	374	708
Revenue Growth (YoY)	325.93%	-11.47%	-83.69%	-47.17%	416.79%
Cost of Revenue	117	38	23	133	137
Gross Profit	113	16	38	241	571
Selling, General & Admin	942	428	351	346	500
Research & Development	-	469	375	303	-
Operating Expenses	942	912	735	666	500
Operating Income	-829	-896	-697	-425	71
Interest Expense	-15	-10	-10	-7	-5
Interest & Investment Income	3	-	-	-	-
Currency Exchange Gain (Loss)	-	-	-	-1	-
Other Non Operating Income (Expenses)	80	36	121	-	78
EBT Excluding Unusual Items	-761	-870	-586	-433	144
Other Unusual Items	-	-	-	-38	-
Pretax Income	-761	-870	-586	-471	144
Income Tax Expense	2	2	3	2	2
Net Income to Company	-763	-872	-589	-473	142
Net Income	-763	-872	-589	-473	142
Net Income to Common	-763	-872	-589	-473	142
Shares Outstanding (Basic)	9	8	8	3	1
Shares Outstanding (Diluted)	9	8	8	3	1
Shares Change (YoY)	9.33%	3.05%	192.85%	432.99%	-
EPS (Basic)	-86.69	-108.31	-75.39	-177.31	283.72
EPS (Diluted)	-86.69	-108.31	-75.39	-177.31	283.72
Free Cash Flow	-581	-768	-581	-631	-
Free Cash Flow Per Share	-66.01	-95.40	-74.37	-236.54	-
Gross Margin	49.13%	29.63%	62.30%	64.44%	80.65%
Operating Margin	-360.44%	-1659.26%	-1142.62%	-113.64%	10.03%
Profit Margin	-331.74%	-1614.82%	-965.57%	-126.47%	20.06%
Free Cash Flow Margin	-252.61%	-1422.22%	-952.46%	-168.72%	-
EBITDA	-792	-858	-657	-362	-
EBITDA Margin	-	-	-	-96.79%	-
D&A For EBITDA	37	38	40	63	-
EBIT	-829	-896	-697	-425	71
EBIT Margin	-	-	-	-113.64%	10.03%
Effective Tax Rate	-	-	-	-	1.39%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.